ReviewBioMed research international2014
The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Nitric Oxide Synthase Dysregulation in Hyperammonemia: Opportunities and Challenges Toward Therapeutic Targeting to Combat Neurological Complications.Neurochemical research · 2026Review
- Plasma levels of NO-related pathway molecules to predict post-transcatheter aortic valve implantation major adverse cardiovascular events: a prospective, multicenter study.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2025Article
- Harnessing Gasotransmitters to Combat Age-Related Oxidative Stress in Smooth Muscle and Endothelial Cells.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Interstage Single Ventricle Heart Disease Infants Show Dysregulation in Multiple Metabolic Pathways: Targeted Metabolomics Analysis.JACC. Advances · 2023Article
- Potential Therapeutic Effects ofPharmaceuticals (Basel, Switzerland) · 2022Review
- Endothelial Dysfunction Driven by Hypoxia-The Influence of Oxygen Deficiency on NO Bioavailability.Biomolecules · 2021Review
- Symmetric Dimethylarginine is Altered in Patients After Myocardial Infarction and Predicts Adverse Outcomes.Journal of inflammation research · 2021Article
- Alterations in Metabolites Associated with Hypoxemia in Neonates and Infants with Congenital Heart Disease.Congenital heart disease · 2020Article
- A Prospective Analysis of Circulating Plasma Metabolites Associated with Ovarian Cancer Risk.Cancer research · 2020Article
- Using clinical and genetic data to predict pulmonary hypertension in bronchopulmonary dysplasia.Acta paediatrica (Oslo, Norway : 1992) · 2018Article
- Nitro-Oleic Acid Prevents Hypoxia- and Asymmetric Dimethylarginine-Induced Pulmonary Endothelial Dysfunction.Cardiovascular drugs and therapy · 2016Article
- Long-Term Chronic Intermittent Hypobaric Hypoxia in Rats Causes an Imbalance in the Asymmetric Dimethylarginine/Nitric Oxide Pathway and ROS Activity: A Possible Synergistic Mechanism for Altitude Pulmonary Hypertension?Pulmonary medicine · 2016Article
- Redox Control of Protein Arginine Methyltransferase 1 (PRMT1) Activity.The Journal of biological chemistry · 2015Article
- Endogenous Asymmetric Dimethylarginine Pathway in High Altitude Adapted Yaks.BioMed research international · 2015Article
- Plasma levels of dimethylarginines in preterm very low birth weight neonates: its relation with perinatal factors and short-term outcome.International journal of molecular sciences · 2014Article
- Relationship of asymmetric dimethylarginine levels with disease severity and pulmonary hypertension in chronic obstructive pulmonary disease.Lung India : official organ of Indian Chest SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since its discovery, many adhere to the view that asymmetric dimethylarginine (ADMA), as an inhibitor of the synthesis of nitric oxide (NO), contributes to the pathogenesis of various diseases. Particularly, this is evident in disease of the cardiovascular system, in which endothelial dysfunction results in an imbalance between vasoconstriction and vasodilatation. Even if increased ADMA concentrations are closely related to an endothelial dysfunction, several studies pointed to a potential beneficial effect of ADMA, mainly in the context of angioproliferative disease such as cancer and fibrosis. Antiproliferative properties of ADMA independent of NO have been identified in this context. In particular, the regulation of ADMA by its degrading enzyme dimethylarginine dimethylaminohydrolase (DDAH) is the object of many studies. DDAH is discussed as a promising therapeutic target for the indirect regulation of NO. In hypoxia-related chronic respiratory diseases, this controversy discussion of ADMA and DDAH is particularly evident and is therefore subject of this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.